| Project/Area Number |
26860205
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Horie Sachiko 東北大学, 加齢医学研究所, 産学官連携研究員 (90451640)
|
|---|
| Research Collaborator |
SATO YASUFUMI 東北大学, 加齢医学研究所, 教授 (50178779)
OBIKA SATORU 大阪大学, 薬学研究所, 教授 (80243252)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | Vasohibin / BNA修飾アンチセンスオリゴヌクレオチド / 抗腫瘍効果 / 肝臓がん / がん / アンチセンスオリゴヌクレオチド / DDS / 癌 / 血管新生 / 肝がんマウスモデル |
|---|
| Outline of Final Research Achievements |
Vasobihin-2 (VASH2), a pro-angiogenic factor, is expressed in cancer cells and promotes tumor growth. This study has shown that the systemic administration of bridged nucleic acids (BNA)-based antisense oligonuculeotide targeting VASH2 accumulated in the liver and exhibited anti-tumor effects on the orthotopic inoculation of a human hepatocellular carcinoma cell line and a metastatic liver cancer model with a splenic inoculation of a human colon carcinoma cell line. Our findings will provide new information and strategy that can be exploited for the development of primary and metastatic liver cancer treatment targeting VASH2.
|
